内容紹介
Summary
We aimed to examine palbociclib toxicity in patients aged 70 years and older with metastatic breast cancer(MBC). From December 2017 to August 2018, 32 patients with estrogen receptor(ER)-positive, human epidermal growth factor receptor 2(HER2)-negative MBC were included in this study. The most common adverse event(AE)observed was neutropenia, and comparative rates of grade 3 or 4 AE were identified in the groups of patients aged ≥70 years(n=11)and<70 years(n=21)(91% vs 81%). Febrile neutropenia occurred in one patient. Although dose interruption rate was higher in the older group( ≥70 years of age)than in the younger group(<70 years of age)(100% vs 86%, respectively), reduction rates were similar between the two groups(64% vs 62%, respectively). Palbociclib was well-tolerated in Japanese older( ≥70 years of age)MBC patients.
要旨
今回われわれは,70歳以上と70歳未満の症例におけるパルボシクリブの有害事象および休薬・減量の割合を比較した。2017年12月～2018年8月までに,パルボシクリブを125 mg/日で開始した症例を対象とした。70歳以上11例,70歳未満は21例であった。最も多い有害事象は好中球減少で,グレード3以上は70歳以上91%,70歳未満で81%の症例で認められた。発熱性好中球減少症は全症例で1例のみであった。70歳以上で休薬の割合は70歳未満と比較し高かった(100% vs 86%)が,減量の頻度は同等であった(64% vs 62%)。高齢患者においてもパルボシクリブは忍容性があると思われた。
目次
We aimed to examine palbociclib toxicity in patients aged 70 years and older with metastatic breast cancer(MBC). From December 2017 to August 2018, 32 patients with estrogen receptor(ER)-positive, human epidermal growth factor receptor 2(HER2)-negative MBC were included in this study. The most common adverse event(AE)observed was neutropenia, and comparative rates of grade 3 or 4 AE were identified in the groups of patients aged ≥70 years(n=11)and<70 years(n=21)(91% vs 81%). Febrile neutropenia occurred in one patient. Although dose interruption rate was higher in the older group( ≥70 years of age)than in the younger group(<70 years of age)(100% vs 86%, respectively), reduction rates were similar between the two groups(64% vs 62%, respectively). Palbociclib was well-tolerated in Japanese older( ≥70 years of age)MBC patients.
要旨
今回われわれは,70歳以上と70歳未満の症例におけるパルボシクリブの有害事象および休薬・減量の割合を比較した。2017年12月～2018年8月までに,パルボシクリブを125 mg/日で開始した症例を対象とした。70歳以上11例,70歳未満は21例であった。最も多い有害事象は好中球減少で,グレード3以上は70歳以上91%,70歳未満で81%の症例で認められた。発熱性好中球減少症は全症例で1例のみであった。70歳以上で休薬の割合は70歳未満と比較し高かった(100% vs 86%)が,減量の頻度は同等であった(64% vs 62%)。高齢患者においてもパルボシクリブは忍容性があると思われた。